Clinical Trial Update: Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) [Phase 3]

View source ↗

Summary

Phase 3 trial assesses efficacy and safety of TAK-438 (vonoprazan) for preventing recurrent gastric or duodenal ulcers in patients receiving NSAID therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer

Drugs mentioned

• TAK-438 (vonoprazan) (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Gastric Ulcers, Duodenal Ulcers | Phase 3 | Status: COMPLETED